When people cannot find a legitimate product, they will search elsewhere.
As global demand for diabetes and weight-loss medications outpaces supply, the World Health Organization warns that a dangerous vacuum has formed — one increasingly filled not with medicine, but with its counterfeit shadow. Since late 2021, medication shortages affecting multiple countries have doubled, and the scarcity of semaglutide-based drugs like Ozempic has drawn criminal actors into the breach. Brazil's health regulator has already identified a suspicious batch in circulation, a reminder that even functioning regulatory systems are not immune. The WHO's counsel is ancient in its simplicity: when the legitimate path is blocked, the detour may cost far more than the destination was worth.
- Global medication shortages have doubled since 2021, with diabetes and weight-loss drugs like Ozempic at the center of a supply crisis that leaves desperate patients with nowhere safe to turn.
- Criminal networks are exploiting the gap, flooding informal markets with counterfeit versions that may contain no active ingredient, toxic impurities, or dangerous bacterial contamination from unsanitary production.
- Brazil's Anvisa has moved the threat from theory to fact, identifying an irregular Ozempic batch — number MP5A064 — after the drug's own manufacturer flagged units that didn't match the genuine product.
- Patients in low- and middle-income countries bear the heaviest burden, increasingly forced into unregulated channels — unlicensed websites, back-alley suppliers — simply to manage chronic conditions.
- The WHO is urging strict adherence to authorized supply chains, while acknowledging that real safety requires solving the underlying shortage, not just warning people away from the dangers it creates.
The World Health Organization has raised a global alarm: medicines are disappearing from legitimate shelves, and counterfeit versions are quietly filling the void. Since September 2021, the number of drugs in short supply across multiple countries has doubled, with the crisis hitting hardest in low- and middle-income nations where patients increasingly turn to unregulated channels out of necessity.
At the center of the storm is semaglutide — the active ingredient in Ozempic — whose explosive rise as both a diabetes treatment and weight-loss drug in 2023 sent demand far beyond what manufacturers could meet. That gap is precisely where criminals operate. Counterfeit versions of the drug are not simply ineffective; they may contain no active ingredient at all, unknown toxic substances, or bacterial contamination born of unsanitary, unqualified production. Patients who unknowingly purchase them risk treatment failure, serious adverse reactions, and worse.
In Brazil, the warning has taken concrete form. Anvisa, the country's health surveillance agency, identified an irregular batch of Ozempic — number MP5A064 — circulating in the market. Tellingly, it was Novo Nordisk itself that first detected units diverging from the genuine product and alerted regulators, a sign that even well-regulated markets are not fully insulated from the problem.
The WHO's guidance is clear: purchase only from authorized, regulated suppliers, and treat informal or secondary channels as genuinely dangerous rather than merely inconvenient. But the organization also acknowledges the harder truth — that warnings alone are insufficient. Until the underlying shortage is resolved and supply restored, the space between what patients need and what they can safely access will remain fertile ground for harm.
The World Health Organization has sounded an alarm about a problem spreading quietly across the globe: medicines are running out, and as they disappear from legitimate shelves, counterfeit versions are filling the void. Since September 2021, the number of medications in short supply across two or more countries has doubled. The shortage is most acute in low- and middle-income nations, where patients desperate for treatment increasingly turn to unregulated channels—back-alley dealers, unlicensed websites, informal networks—to find what they cannot obtain through official means.
The WHO has identified a specific culprit driving this dangerous trend: the global scarcity of diabetes and weight-loss medications, particularly semaglutide, the active ingredient in Ozempic. The injectable pen, used to control appetite and manage type 2 diabetes, became a household name in 2023 as demand surged far beyond what manufacturers could supply. That gap between demand and supply creates opportunity for criminals. When people cannot find a legitimate product, they will search elsewhere. And when they search elsewhere, they often find something that looks right but is not.
Counterfeit medicines are not merely ineffective. They are dangerous. A fake drug may contain no active ingredient at all, leaving a patient's condition untreated. Or it may contain unknown impurities, toxic substances, or bacterial contamination from production in uncontrolled, unsanitary conditions by unqualified workers. The WHO warns that these products have never been approved or monitored by any health authority. They carry the risk of serious adverse reactions, organ damage, or worse. Patients who buy them are gambling with their health, often without knowing it.
In Brazil, the problem has moved from abstract warning to concrete reality. This month, the country's National Health Surveillance Agency, known as Anvisa, identified an irregular batch of Ozempic circulating in the market. The batch number is MP5A064. Notably, it was the manufacturer itself—Novo Nordisk Farmacêutica do Brasil Ltda, the company that holds the official registration for the drug in Brazil—that discovered units with characteristics diverging from the genuine product and reported the finding to regulators. This suggests that even in a country with a functioning regulatory system, counterfeit or substandard versions can slip into distribution channels.
The WHO's message to patients is direct: buy only from authorized, regulated suppliers. Be vigilant when purchasing from secondary sources. Understand that obtaining medicines through unauthorized or informal channels is not merely inconvenient or slightly risky—it is a behavior with potentially grave consequences. The organization acknowledges that shortages create a genuine hardship, leaving patients in a bind. But the solution is not to bypass safety systems. It is to address the underlying shortage, to increase supply, and to strengthen the systems that protect people from harm. Until that happens, the gap between what people need and what they can safely obtain will remain a space where danger thrives.
Notable Quotes
The shortage of medications is a recognized driver for counterfeit or substandard drugs, and creates risk that many will seek medicines through unofficial channels like the internet.— World Health Organization
Counterfeit medical products lack efficacy, cause toxic reactions, are not approved or controlled by competent authorities, and may be produced in unhygienic conditions by unqualified personnel.— World Health Organization
The Hearth Conversation Another angle on the story
Why would a manufacturer report its own counterfeit product to regulators? Doesn't that hurt their business?
It actually protects their business. If fake Ozempic circulates and harms patients, people lose trust in the brand entirely. The manufacturer's reputation and legal liability are at stake. Reporting it is damage control.
But the WHO says shortages are driving this. So isn't the real problem that there simply isn't enough Ozempic to go around?
Exactly. The shortage is the root cause. When supply can't meet demand, people get desperate. They'll buy from anyone. The counterfeiting is a symptom of a broken supply chain, not the disease itself.
What happens to someone who injects a countaminant-filled fake?
It depends. They might feel nothing—the drug is inert, so their diabetes or weight stays uncontrolled. Or they might get very sick. Unknown impurities, bacterial contamination, toxic reactions. They won't know what hit them until symptoms appear, and by then it's hard to trace back to the fake injection.
Is this just a Brazil problem?
No. Brazil is where it was caught. But the WHO is warning about a global surge. Low- and middle-income countries are hit hardest because they have fewer resources to monitor supply chains and less access to legitimate stock. It's a worldwide issue.
So what's the fix?
The WHO says buy only from authorized suppliers. But that's advice for people who have access to authorized suppliers. For someone in a country where Ozempic is scarce and expensive, that's not really a solution. The real fix is increasing production and distribution.